Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis
- 19 March 2026
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 46 (4) , e70607
Abstract
Background & Aims: Terlipressin is crucial for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). This meta‐analysis compared the continuous versus bolus terlipressin infusion for treating the above conditions in patients with cirrhosis. Methods: Three major databases were searched for randomised controlled trials (RCTs) comparing two infusion strategies. A meta‐analysis was conducted to estimate the risk ratios (RR) with a 95% confidence interval (CI) based on a random‐effects model. Subgroup analyses were performed to account for adverse events (AEs) in terms of severity and organ systems. Additionally, a dose–response analysis was conducted to evaluate the correlation between drug dosage and AEs. Result: Six RCTs (494 patients) were included. Compared with bolus infusion, continuous terlipressin infusion showed less treatment failure (RR, 0.32; 95% CI, 0.12–0.87; p = 0.03), less rebleeding (RR, 0.52; 95% CI, 0.33–0.81; p < 0.01) and a trend toward lower mortality (RR, 0.62; 95% CI, 0.30–1.28; p = 0.19) in patients with AEVB, while response rates were comparable in patients with HRS (RR, 1.11; 95% CI, 0.87–1.41; p = 0.40) and a risk reduction of total AEs (RR, 0.59; 95% CI, 0.45–0.76; p < 0.01). Subgroup analyses stratifying AEs supported these findings, and a correlation was noted between drug dose and cardiovascular AEs. Conclusion: Compared to bolus administration, continuous terlipressin infusion reduces treatment failure and rebleeding rates in patients with AEVB; provides a comparable response rate in patients with HRS; and decreases the incidence of total, severe, and cardiovascular AEs while allowing for lower overall doses.Keywords
This publication has 24 references indexed in Scilit:
- Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleedingHepatology International, 2022
- Determining the efficacy of continous vs intermittent adminstration of terlipressin for control of acute esophageal variceal bleed in portal hypertensionJournal of Clinical and Experimental Hepatology, 2022
- Comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: An open-label randomized controlled trialIndian Journal of Gastroenterology, 2018
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled studyHepatology, 2016
- Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysisHepatology International, 2014
- Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhageHepatology, 2014
- Recent advances in our understanding of hepatorenal syndromeNature Reviews Gastroenterology & Hepatology, 2012
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liverIntensive Care Medicine, 2007
- Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?Intensive Care Medicine, 2007